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Summary. Background and objectives: The range of plasma
concentrations of hemostatic analytes in the population is wide.
In this study these components of blood coagulation phenotype
are integrated in an attempt to predict clinical risk.
Methods: We modeled tissue factor (TF)-induced thrombin
generation in the control population (N ¼ 473) fromtheLeiden
Thrombophilia Study utilizing a numerical simulation model.
Hypothetical thrombin generation curves were established by
modeling pro- and anticoagulant factor levels for each
individual. These curveswere evaluated using parameterswhich
describe the initiation, propagation and termination phases of
thrombin generation, i.e. time to 10 nM thrombin (approximate
clot time), total thrombin and the maximum rates and levels of
thrombin generated. Results and conclusions: The time to
10 nM thrombin varied over a 3-fold range (2.9–9.5 min),
maximum levels varied over a  4-fold range (200–800 nM),
maximum rates varied 4.8-fold (90–435 nM min)1) and total
thrombin varied 4.5-fold (39–177 lM s)1) within this control
population. Thrombin generation curves, deﬁned by the
clotting factor concentrations, were distinguished by sex, age,
body mass index (BMI) and oral contraceptive (OC) use. Our
results show that the capacity for thrombin generation in
response to a TF challenge may represent a method to identify
an individual’s propensity for developing thrombosis.
Keywords: coagulation, factor levels, numerical simulators,
thrombin proﬁles, risk factors.
Introduction
An individual without apparent coagulopathy and a coagula-
tion protein proﬁle where each factor level falls within the
normal range of its mean plasma level [1] may still be at
increased risk of thrombosis. Clinical screening techniques to
determine alterations in hemostasis rely primarily on clot based
assays, i.e. the prothrombin time (PT) [2] and the activated
partial thromboplastin time (APTT) [3]. These assays, while
useful in deﬁning dramatic hemostatic defects, whether of
genetic or pharmacological origin, fail to discriminate individ-
uals at risk for thrombotic syndromes.
The causes of thrombosis can be viewed in a hierarchy: clear-
cut quantitative and qualitative defects, based on single gene
mutations with loss of function (antithrombin [4,5], protein C
[6,7] and protein S [8,9] deﬁciency); gain-of-function variants,
such as factor (F)V Leiden [10,11] and prothrombin G20210A
[12,13]; and high levels of procoagulant factors [notably factor
(F)VIII [14], factor (F)IX [15], factor XI [16]] without a clear
genetic substrate. Thus, thrombosis is amulticausal disorder, in
which genetic and environmental factors (i.e. obesity [17,18],
oral contraception [19,20], hormone replacement therapy [20],
age [21] and alcohol use [22]) potentially interact. Therefore, a
combinatorial approach appears needed to evaluate thrombo-
sis risk.
One approach incorporates epidemiological studies in which
the contribution to risk of all possible combinations of risk
factors is estimated and evaluated with clinical thrombosis as
the outcome. The second approach focuses on developing tests
for assessing hemostatic competence, with a primary focus on
the measurement of thrombin generation. These in vitro
approaches include the whole blood thrombin generation test
[23,24], the endogenous thrombin potential in plasma [25], or
derived methods in which markers of procoagulant [26,27] or
ﬁbrinolytic activity [28–30] are measured.
Thrombin generation curves can be operationally charac-
terized as displaying initiation, propagation, and termination
phases [31]. During the initiation phase, minute amounts of
thrombin are formed in events, which include: exposed or
expressed tissue factor (TF) binding to circulating factor
(F)VIIa [32,33]; activation of the zymogens FIX and factor
(F)X [34,35]; and conversion of prothrombin to thrombin by
FXa [36,37]. This initial thrombin is responsible for the
activation of platelets, coagulation procofactors FV and FVIII
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and the resulting assembly of the membrane-bound
coagulation enzyme complexes. Clot formation occurs when
approximately 2–10 nM thrombin is generated [23,24] and
coincides with the onset of the major burst of thrombin
generation, which occurs during the propagation phase. In
this text we approximate clot time as the time to 10 nM
thrombin (as thrombin–antithrombin III).] During this phase
the majority of thrombin ( 96%) is generated in a process
undetected by clot-based assays. The propagation phase of
thrombin generation is associated with clinical bleeding risk in
hemophilia [38–41], anticoagulant [42,43] and antiplatelet
[43,44] therapies. The necessary concentrations of thrombin
required to yield adequate hemostasis have not been deter-
mined; however, knowledge that thrombin generation is
essential to hemostasis is well established.
Advances in mathematical algorithm development and
biochemical analyses have enabled modeling of the complex
hemostatic system [45–48]. Descriptions of association states,
membrane-bindingparameters, enzymecomplexassembly,pro-
and anticoagulant reaction kinetics have been developed. These
data permit hypothetical analytical descriptions of the multi-
component pathway of TF-initiated blood coagulation [48].
These numerical simulations of thrombin generation are
comparable to thrombingenerationcurvesobserved insynthetic
plasmas and in whole blood [26,49–52]. Numerical simulations
allow the exploration of well-deﬁned clinical databases to
generate retrospectively population-based thrombin curves as a
potential contributor to thrombosis risk analyses.
In the present study we utilize the quantitative coagulation
factor concentration data for the control population of the
Leiden Thrombophilia Study (LETS) [53] to generate com-
prehensive thrombin generation curves for apparently healthy
individuals. The combination of numerical simulations with
the well-characterized LETS population permits evaluation of
the utility of theoretical thrombin generation proﬁles with
other risk factors (i.e. sex, birth control, obesity) to evaluate
the general population. This study aims to develop a
composite measure that can be used to assess the non-diseased
population for potential prothrombotic or prohemorrhagic
phenotypes.
Materials and methods
Study population
The LETS [53] is a case–control study where 474 patients with
an objectively diagnosed ﬁrst deep vein thrombosis (DVT,
enrollment 1 January 1988 to 31 December 1992) were inclu-
ded, as well as the same number of sex- and age-matched
controls. The patients were selected from three anticoagulation
clinics in the Netherlands. The healthy controls were acquaint-
ances of the patients or partners of other patients. Patients with
known malignancies were excluded and all patients were
<70 years. For our study, we focus on the control group, of
which one individual on oral anticoagulation was excluded
from these evaluations.
Blood collection and coagulation protein analyses
As previously described [53], whole blood (0.9 vol) was
collected from the antecubital vein into Sarstedt Monovette
tubes (Nu¨mbrecht, Germany) containing 0.106 M of trisodium
citrate (0.1 vol). Plasma was prepared by centrifugation for
10 min at 2000 · g at room temperature and stored in aliquots
at )70 C until assayed. The measurements of the levels of the
coagulation proteins factor (F)II, FVII, FV, FVIII, FIX, FX,
tissue factor pathway inhibitor (TFPI) and antithrombin (AT)
were described in detail in earlier studies performed in the
LETS population [14,15,53–58]. In brief, FII activity was
measured by a chromogenic assay using Echis carinatus venom
as an activator [58]. FV:Ag was measured by an in-house-
developed sandwich-type enzyme linked immunosorbent assay
(ELISA) with two differentmonoclonal antibodies, bothwith a
high afﬁnity for the light chain of activated FV [54]. The FVII
and FVIII activities were measured by one-stage coagulation
assays [14,59]. FIX and FX antigen levels were measured by
sandwich ELISAs using commercial polyclonal antibodies
(Dako A/S, Glostrup, Denmark) [15,57]. TFPI total antigen
was measured with a commercial ELISA (Asserachrom Total
TFPI; Diagnostica Stago, Asnieres, France) [56].
Numerical simulations
The numerical model of the extrinsic coagulation system
[48–51] provides a method for investigating thrombin genera-
tion proﬁles and patterns in a large group of individuals.
Computationally generated active thrombin proﬁles (thrombin
plus meizothrombin) are obtained utilizing a software package
termed Clot Speed-II [48]. This program uses a web-based
interface with a generally applicable fourth order Runge–Kutta
solver that provides solutions to a family of time-dependent
differential equations. Thismodel was adjusted to takemultiple
individuals’ factor levels by running the solver on each
individual simultaneously. Nine reactants are included in the
current model: procoagulant FII, FV, FVII/VIIa, FVIII, FIX,
FX and the anticoagulants AT and TFPI. Individual factor
levels were obtained on each of the 473 healthy controls and
translated into molar (M) concentrations using literature values
for the mean plasma concentrations [48]. Following data entry,
simulations were initiated with a 5-pM TF stimulus and solved
for active thrombin species present at 1-s intervals over 20 min.
Each individual’s time course of active thrombin was
analyzed using the following parameters: time to 10 nM
thrombin (estimated clot time [23,24]); maximum rate of
thrombin generation; maximum level of thrombin generation;
and area under the thrombin curve. The area under the
thrombin curve is calculated by summing active thrombin
concentrations at each time point.
Several individual characteristics were used to deﬁne sub-
populations. We separated the data by sex (male n ¼ 201 and
female n ¼ 272), oral contraceptive use (no n ¼ 99 and yes
n ¼ 54), age (£ 45 years n ¼ 223 and >45 years n ¼ 250),
smoking (no n ¼ 305 and yes n ¼ 168), alcohol use (none n ¼
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111, £1 drink day)1 n ¼ 222, 2–4 drink day)1 n ¼ 124, 5–
10 drink day)1 n ¼ 11), and body mass index (BMI
£26 kg m)2 n ¼ 275, >26 kg m)2 n ¼ 193). In the alcohol
category ﬁve individuals were excluded because of an unknown
alcohol history. The thrombin generation curves of each
subpopulation were generated by averaging thrombin concen-
trations at each time point. Subpopulation thrombin proﬁles
are shown as themean values with the 95% conﬁdence interval.
Additionally, we investigated for each individual whether
one factor or the combination of factor levels dominated the
outcome of active thrombin generation proﬁles. Eight simula-
tions were run (FII, FV, FVII, FVIII, FIX, FX, AT and TFPI)
independently for all 473 individuals in which one of the eight
factor levels was set to 100%, while the other seven were the
actual values from each individual. FVIIa was estimated as
0.1% of the FVII concentration [60]. The resulting 4257
thrombin generation proﬁles were divided into nine groups
(eight reﬂecting the factor held constant and one for the actual
values). For each individual within a group, the four thrombin
parameters were extracted and groupmeans generated for each
parameter. Comparisons between the mean and the standard
deviation of each of the four parameters from the group
reﬂecting the actual factor values were made to each of the four
parameters characterizing each of the other eight groups.
Statistical analyses
Differences between parameters and individual categories were
evaluated by means and standard deviations (SD). The 95%
conﬁdence interval (CI) was calculated by CI95% ¼ differ-
ence ± 1.96 · standard error (SE), where the difference ¼
mean1 ) mean2 and the SE ¼ square root of (SD12/
N1 + SD2
2/N2). The 95% CI of the thrombin generation
curves, shown in Figs 1 and 3, represents the interval that
permits the description of 95% of the range of normally
distributed values.
Results
Baseline characteristics of the LETS control population are
shown in Table 1. The factor levels for all the individuals for
FII, FV, FVII, FVIII, FIX, FX, AT and TFPI are shown in
Table 2 as mean and SD. As has been published previously
[14,15,53–59], the ranges were as follows: FII 55–153%, FV
47–302%, FVII 41–171%, FVIII 49–232%, FIX 52–188%,
FX 46–163%, AT 63–125% and TFPI 46–170%. These
ranges, excluding FV, are similar to standard clinical labora-
tory ﬁndings. FV levels in this control population were higher
than average [54].
Consequences of each individual’s inventory
Four hundred and seventy-three comprehensive thrombin
generation curves were obtained from the factor levels of these
individuals. The time-dependent dynamics over a 20-min time
frame in regards to active thrombin proﬁles for the population
were averaged and shown in Fig. 1A with the SD (gray). The
average maximum level was 294 nM (SD 136 nM) with a time
to 10 nM thrombin of 4.7 min (SD 3.7 min). This large
deviation in maximum level and time to 10 nM thrombin
illustrates the variety in individual simulations for a healthy
population. Therefore, we investigated the control popu-
lation for the time it takes to get to the maximum level of
active thrombin. The mean for the time to maximum thrombin
was 10.6 min (SD 1.4 min). We separated two groups (2 SD
from the mean), one with a fast time to the maximum
level (n ¼ 13) and one with a slow time to maximum level
(n ¼ 13) (Fig. 1A). The maximum level in the fast group was
579 nM (SD 49 nM) thrombin at 7.6 min (SD 0.2 min). The
slow group had lower maximum levels of 368 nM (SD 41 nM)
and took longer to reach 10 nM thrombin, 14.4 min (SD
0.7 min). The SD of these two populations is seen in the inset
in Fig. 1A. Overall, these simulations illustrate that there
are individuals within the average population that generate
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Fig. 1. Thrombin proﬁles of healthy individuals. (A) Factor levels
from 473 healthy individuals were input into Clot Speed II and initiated
with a 5-pM stimulus of tissue factor and solved for active thrombin over
a 20-min time frame (same as whole blood assays). The mean simulation
with the standard deviation (294 ± 136 nM) at all the time points is
shown as the center curve. A fast (7.6 ± 0.2 min and max. levels of
579 ± 49 nM thrombin) and slow (14.4 ± 0.7 min and a maximum
level of 368 ± 41 nM thrombin) population (N ¼ 13 per group) were
separated out and compared with the average time it takes to reach
maximum thrombin levels (10.6 ± 1.4 min). The inset panel shows the
standard deviation of these populations. (B) Thrombin simulations for
three individuals; a low-, mid- and high-thrombin generator. From left
to right, the individual in the ﬁrst curve had maximum thrombin levels
of 778 nM, the second individual (middle curve) had maximum thrombin
levels of 436 nM, and the last individual had maximum levels of 196 nM
thrombin.
1474 K. Brummel-Ziedins et al
 2005 International Society on Thrombosis and Haemostasis
Clot TimeA B
C D
Maximum Rate of Thrombin
Maximum Level of Thrombin Total Thrombin
70
60
50
40
30
20
10
0 3.00
3.67
4.33
5.00
5.67
6.33
7.00
7.67
8.33
9.00
9.67
250
200
300
350
400
450
500
550
600
650
700
750
120
90 150
180
210
240
270
300
330
360
390
420
5040 60 70 80 90 100
110
120
130
140
150
160
170
70
60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
Fig. 2. Histograms of the thrombin parameters for the healthy population. Parameters that are used for pattern recognition are (A) time to 10 nM
thrombin (min, estimated clot time); (B) maximum rate of thrombin generated (nM min)1); (C) maximum level of thrombin generated (nM); (D) total
thrombin generated (lMS, area under the curve).
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Fig. 3. The inﬂuence on thrombin generation by potential risk factors. Numerical simulations were performed on the groups of individuals that fell
within each risk factor category. Coagulation was initiated with a 5-pM stimulus of tissue factor and thrombin generation was followed for 20 min. The risk
factors are: (A) Sex; women (n ¼ 272) and men (n ¼ 201); (B) age; minimum age 45 years (n ¼ 250) and maximum age 45 years (n ¼ 223); (C) body mass
index (BMI) £26 kg m)2 (n ¼ 275) and >26 kg m)2 (n ¼ 193); (D) oral contraceptives (OC); OC use (n ¼ 54) and no OC use (n ¼ 99). All thrombin
generation curves are shown as the mean and 95% CI.
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large quantities of thrombin fast (potentially prothrombotic)
and there are individuals that take a longer time to generate
lesser amounts of thrombin (potentially protected from
thrombosis).
To illustrate these simulations we extracted three individ-
uals, a low-, mid- and high-level thrombin generator
(Fig. 1B). The maximum level of thrombin is a time-
independent parameter, unlike the average simulation shown
in Fig. 1A, which is time dependent. For the low thrombin
generator, the factor levels were: FII 63%, FV 111%, FVII
102%, FVIII 152%, FIX 77%, FX 115%, AT 122%, and
TFPI 100%. The mid thrombin generator had factor levels
of: FII 110%, FV 135%, FVII 111%, FVIII 101%, FIX
93%, FX 108%, AT 98%, and TFPI 92%. The high
thrombin generator had factor levels of FII 153%, FV
127%, FVII 112%, FVIII 167%, FIX 151%, FX 126%,
AT 100%, and TFPI 81%. Their maximum level and time
to 10 nM thrombin (parentheses) were: 196 nM (8.9 min);
436 nM (5.0 min); 778 nM (3.5 min). Decreasing maximum
thrombin levels corresponded to decreased prothrombin
levels. Interestingly, the individual that had the highest level
of thrombin also had the shortest clot time.
Thrombin parameters
The heterogeneity of thrombin generation within the popula-
tion was evaluated by investigating individual simulations for
the initiation, propagation and termination phases of thrombin
generation by the parameters: time to 10 nM thrombin,
maximum rate of thrombin generated, maximum level of
thrombin generated and total thrombin. These latter para-
meters are time independent and individualized. Therefore, we
could evaluate the control population for patterns of thrombin
formation that can distinguish individuals from each other.
Each parameter is shown as a histogram in Fig. 2A–D. The
range of time to 10 nM thrombin for all 473 individuals was
Table 1 Standard clinical data
N
PT
(SD), s
APTT
(SD), s
Fibrinogen
(SD), mg mL)1
All 473 11.7 (0.6) 28.0 (2.3) 3.3 (0.7)
Sex
Men 201 11.8 (0.6) 28.2 (2.5) 3.2 (0.7)
Women 272 11.7 (0.6) 27.9 (2.2) 3.3 (0.6)
Oral contraceptive
No 99 11.8 (0.6) 28.0 (2.3) 3.2 (0.6)
Yes 54 11.6 (0.6) 27.8 (2.3) 3.4 (0.7)
Age (years)
£ 45 223 11.8 (0.6) 28.1 (2.3) 3.2 (0.6)
> 45 250 11.7 (0.6) 27.9 (2.4) 3.4 (0.7)
Smoke
No 305 11.8 (0.6) 28.0 (2.3) 3.2 (0.6)
Yes 168 11.7 (0.6) 28.1 (2.4) 3.4 (0.7)
Alcohol (drinks per day)
None 111 11.7 (0.6) 27.9 (2.3) 3.4 (0.7)
£ 1 222 11.8 (0.6) 28.0 (2.4) 3.3 (0.6)
2–4 124 11.7 (0.6) 28.1 (2.3) 3.2 (0.7)
5–10 11 12.1 (0.6) 27.5 (1.0) 3.0 (0.4)
> 10 5 11.9 (0.3) 28.6 (1.4) 2.9 (0.4)
BMI
£ 26 275 11.8 (0.6) 27.9 (2.3) 3.1 (0.6)
> 26 193 11.6 (0.5) 28.1 (2.4) 3.4 (0.7)
Normal healthy range* 10.7–13.4 23.4–29.8 2.0–3.7
*As determined by the Department of Hematology, Leiden University
Medical Center, the Netherlands. N, Population size; PT, prothrombin
time; APTT, activated partial thromboplastin time; BMI, body mass
index, weight to height ratio kg m)2; SD, standard deviation.
Table 2 Clinical factor levels
N
FII %
mean (SD)
FV %
mean (SD)
FVII %
mean (SD)
FVIII %
mean (SD)
FIX %
mean (SD)
FX %
mean (SD)
AT %
mean (SD)
TFPI total %
mean (SD)
All 473 103.7 (14.7) 131.4 (32.5) 110.5 (21.7) 121.8 (32.6) 103.0 (21.0) 103.5 (17.2) 99.1 (10.4) 92.0 (22.7)
Sex
Men 201 101.7 (14.9) 136.7 (34.9) 107.1 (20.1) 119.6 (32.3) 105.0 (19.5) 103.6 (14.7) 98.7 (11.0) 99.0 (23.9)
Women 272 105.2 (14.5) 127.5 (30.1) 113.0 (22.5) 123.4 (32.7) 101.6 (21.9) 103.4 (18.9) 99.4 (9.9) 86.8 (20.3)
Oral contraceptive
No 99 101.8 (14.1) 122.9 (27.0) 104.3 (20.7) 118.1 (32.1) 92.8 (18.8) 95.1 (16.5) 100.6 (9.8) 85.7 (16.8)
Yes 54 107.4 (14.9) 112.7 (27.1) 119.4 (23.4) 125.8 (32.9) 115.5 (23.3) 118.0 (19.0) 95.5 (10.2) 68.0 (13.7)
Age (years)
£ 45 223 103.2 (14.5) 122.4 (29.5) 107.2 (23.3) 115.1 (30.7) 100.0 (20.5) 104.2 (18.1) 100.4 (10.2) 85.8 (19.9)
> 45 250 104.2 (14.9) 139.4 (33.1) 113.4 (19.7) 127.7 (33.1) 105.7 (21.0) 102.8 (16.3) 97.9 (10.4) 97.5 (23.7)
Smoke
No 305 103.4 (15.3) 130.3 (31.4) 111.0 (21.5) 124.6 (32.7) 100.7 (20.2) 101.6 (16.6) 99.0 (10.7) 91.5 (22.5)
Yes 168 104.3 (13.6) 133.2 (34.5) 109.5 (22.1) 116.6 (31.9) 107.2 (21.6) 106.9 (17.8) 99.3 (9.8) 92.9 (23.2)
Alcohol (drinks per day)
None 111 105.1 (14.0) 133.1 (32.1) 110.4 (22.5) 124.1 (34.9) 101.8 (21.3) 104.1 (19.4) 99.2 (10.2) 91.3 (21.9)
£ 1 222 103.7 (14.3) 128.6 (28.9) 111.1 (20.3) 121.8 (33.2) 101.1 (20.4) 101.4 (17.3) 99.4 (10.9) 89.8 (24.3)
2–4 124 102.2 (15.7) 135.9 (38.6) 110.1 (22.9) 119.6 (30.1) 107.4 (21.6) 105.9 (14.5) 98.6 (9.8) 95.8 (20.7)
5–10 11 104.9 (21.4) 133.1 (25.0) 93.5 (22.5) 119.3 (30.8) 110.3 (17.2) 113.2 (16.5) 96.3 (9.3) 103.0 (15.3)
BMI (kg m)2)
£ 26 275 101.9 (14.2) 127.8 (32.3) 108.8 (22.6) 118.1 (30.5) 99.7 (21.1) 101.4 (17.0) 100.3 (10.2) 92.4 (21.9)
> 26 193 106.4 (15.0) 136.6 (32.5) 113.6 (19.7) 127.1 (35.0) 108.2 (19.6) 106.9 (17.0) 97.3 (10.5) 91.8 (24.0)
N, Population size; F, factor; AT, antithrombin; TFPI, tissue factor pathway inhibitor; BMI, body mass index.
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2.9–9.5 min, with a mean and SD of 5.3 min (SD 1.1 min)
(Fig. 2A).These simulationswere initiatedwith a 5-pM stimulus
of TF and resulted in an average time to 10 nM thrombin that
correlated with whole blood clot times (5.8 min, SD 1.0 min)
initiated with the same concentration of TF [26]. At a ﬁxed cut-
off of thrombin generation at the <5th percentile (P5), we
identiﬁed 21 individuals (4.4%of the population) with a time to
10 nM of <3.5 min. At the >95th percentile (P95) we
identiﬁed 23 individuals that had levels >7.3 min.
For the maximum rate of thrombin parameter (Fig 2B),
the range was 90–435nM/min, and the mean was 210nM/min
(SD 60nM/min); levels £128nM/min and ‡319nM/min rep-
resent the P5 and P95 extremes. The maximum level
parameter had a range of thrombin from 200 to 780nM,
with a mean of 440nM (SD 90nM) (Fig 2C). The extremes
were £311nM (P5) and ‡650nM (P95). This range of
thrombin maximum levels in the LETS control population
(n ¼ 473), overlap the maximum levels determined in an
empirical whole blood study of 13 healthy individuals (245–
775nM, with a cumulative mean of 414nM, SD 111nM) (26).
The mean of the population for total thrombin (Fig 2D)
was 92lMs (SD 19lMs) with a range of 39–177lMs. The
extremes of this parameter were £65lMs (P5) and ‡125lMs
(P95).
Overall, in regards to the outliers in the <P95 category,
30% of the same individuals were found in three of the four
categories: lower maximum rate, less total thrombin, and lower
maximum levels. Of these individuals, 13% were also in the
>P95% category for taking longer to reach clot time
(decreased time to 10 nM thrombin). In regards to the >P95
category, 26% of the same individuals were found in three of
the four categories: higher maximum rate, more total throm-
bin, and higher maximum levels. Of these individuals, only
13% were also in the <P5% category for faster clot times
(increased time to 10 nM thrombin). Thus, the same individuals
are not at the extremes of the thrombin parameters in all cases.
The effect of individual factor levels on the computational
model is shown in Table 3. Clot time was affected by a
maximum of 5.7% over the actual values in two of the
eight factors tested (FV and TFPI). Maximum level was
affected by seven of the eight factors tested in the order of:
FII >FVIII >TFPI > FV >AT >FIX. The range of
effect on the maximum level parameter was 0.6–3.9%.
Maximum rate varied up to 8.2% when FVIII was held
constant and 5.3% when TFPI was held constant. The only
factor that had an inﬂuence on total thrombin production
was FII (by 5.4%).
Determinants of thrombin generation
We evaluated the inﬂuence of sex, age, BMI, alcohol use,
smoking habits and oral contraceptives on the parameters of
thrombin generation (Table 4). The 272 women who were
evaluated included women on oral contraceptives and in
menopause. Women clotted faster than men (5.0 min, SD
1.1 min, vs. 5.6 min, SD 1.1 min) and reached higher levels
of thrombin (448 nM, SD 86 nM vs. 419 nM, SD 81 nM)
at a faster rate (218 nM min)1, SD 61 nM min)1 vs.
195 nM min)1, SD 51 nM min)1) than men. Total thrombin
was similar in women and men.
Thrombin generation was markedly enhanced in women
who used oral contraceptives. This analysis was restricted to
premenopausal women aged 15–49 years, who were not
pregnant at the index date (n ¼ 10), nor within 30 days
postpartum (n ¼ 14), had not had a recent miscarriage
(n ¼ 2) or did not use only depot contraceptives (n ¼ 3).
We found that women on oral contraceptives (n ¼ 54) were
predicted to clot faster (mean difference 1.2 min, CI 0.9,
1.5), produce more total thrombin (mean difference 14 lMS,
CI 8, 20) and at higher maximum levels (mean difference
93 nM, CI 65, 121) that were generated at a faster rate
(mean difference 76 nM min)1, CI 56, 96) than women who
were not on oral contraceptives.
Individuals (both men and women) who were older
(> 45 years old) had signiﬁcantly more total thrombin (mean
difference 5 lMS, CI 1.7, 8.3) than individuals who were
younger (< 45 years old). Time to 10 nM thrombin, maximum
level and rate were not markedly different.
When we investigated BMI (in all individuals combined),
all four thrombin parameters were affected in individuals
who had a BMI >26 kg m)2. Compared with subjects with
a BMI <26 kg m)2, these individuals had greater total
thrombin (mean difference 9 lMS, CI 5.5, 12.5), maximum
levels of thrombin (mean difference 43 nM, CI 28, 58), faster
Table 3 Individual protein inﬂuence on thrombin parameters
Protein held constant
Time to 10 nM thrombin,
mean, min (SD)
Maximum level of thrombin,
mean, nM (SD)
Maximum rate of thrombin,
mean, nM min)1 (SD)
Total thrombin,
mean, lMS (SD)
Normal LETS* 5.3 (1.1) 436 (85) 208 (58) 92 (19)
FII 5.3 (1.1) 419 (59) 201 (50) 87 (12)
FV 5.6 (1.2) 442 (86) 215 (59) 91 (19)
FVII 5.3 (1.1) 435 (85) 208 (57) 92 (19)
FVIII 5.3 (1.2) 421 (77) 191 (44) 92 (19)
FIX 5.3 (1.1) 433 (77) 205 (48) 92 (19)
FX 5.2 (1.1) 437 (91) 211 (63) 91 (19)
AT 5.3 (1.0) 431 (81) 206 (54) 90 (17)
TFPI 5.6 (0.8) 426 (81) 197 (49) 92 (19)
*Results obtained from the LETS database. F, Factor; AT, antithrombin; TFPI, tissue factor pathway inhibitor.
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rates of thrombin generation (mean difference 25 nM min)1,
CI 15, 35) and a faster clot time (mean difference 0.4 min,
CI 0.2, 0.6). Alcohol consumption and smoking did not
clearly affect thrombin parameters.
The dynamic simulations from the inﬂuence of sex, age,
BMI and oral contraceptives on thrombin generation are
seen in Fig. 3. The most pronounced inﬂuence on thrombin
generation was the use of oral contraceptives (Fig. 3D).
Synergy of the pro- and anticoagulants in influencing
thrombin parameters
On comparing the various categories for individual factor
levels (Table 2), we saw that women had higher FII (3.5%,
CI 0.8, 6.2) and FVII (5.9%, CI 2.0, 9.8) and lower FV
(9.2%, CI 3.2, 15.2) and TFPI (12%, CI 8, 16), while
FVIII, FIX, FX and AT were not different between the
sexes. The use of oral contraceptives in women showed a
similar pattern, with increased FII and FVII and decreased
FV and TFPI levels. However, FIX (23%, CI 15, 30) and
FX levels (23%, CI 17, 29) were increased when women
used oral contraceptives. Interestingly, the oral contraceptive
user group had lower levels of both AT and TFPI. This
decreased suppression of coagulation could explain why oral
contraceptive users clot faster, have higher rates, maximum
levels and more total thrombin than non-users.
Individuals older than 45 years had higher procoagulants:
FV (17%, CI 11, 23), FVII (6.2%, CI 2.3, 10), FVIII (13%, CI
7, 18), FIX (5.7%, CI 2, 9.4) and the anticoagulant TFPI (12%,
CI 8, 16). AT was the only factor lower with increasing
age. Increasing BMI (> 26 kg m)2) resulted in all of the
procoagulants being higher and only the anticoagulant AT
(3%, CI 1.1, 4.9) being lower. TFPI levels were similar between
high and low BMI levels.
Small changes were seen in the coagulation factor levels from
the effect on alcohol. Versus non-drinkers, only FIXwas higher
in the 2–4 drink population (mean difference 5.6%, CI 0.1,
11.0. In the 5–10 drinks per day population, FVII was less
(mean difference 17%, CI 3, 31) and TFPI was higher (mean
difference 12%, CI 2, 22) in the drinking population. There
were no signiﬁcant changes between the factor levels in the £1
drink per day category versus non-drinkers. When individuals
smoked, the levels for FIX (mean difference 6.5%, CI 2.5, 10.5)
and FX (mean difference 5.3%, CI 2.0, 8.6) increased and
FVIII decreased (mean difference 8%, CI 1.9, 14.1). These
results tell us that the differences between thrombin generation
curves illustrated in Fig. 3 are not due to just one factor
contributing to the shift in thrombin generation. It is the
combination of the synergy between the pro- and anticoagulant
factors that results in individuals potentially being more or less
prothrombotic, which appears to be inﬂuenced by age, sex, oral
contraceptive use, and BMI. Although changes were seen
between the factor levels for the smoking and alcohol
consumption populations, no deﬁned effect on thrombin
generation was observed.
Discussion
This study was used to predict how the TF-generated
thrombin generation process might vary in healthy individuals
in a large population (n ¼ 473) and suggested that there are
individuals who are potentially more at risk than others for
Table 4 Thrombin parameters and inﬂuences from other risk factors
N
Time to 10 nM
thrombin,
mean, min (SD)
Maximum level
of thrombin,
mean, nM (SD)
Maximum rate of
thrombin, mean,
nM min)1 (SD)
Total thrombin,
mean,
lMS (SD)
All 473 5.3 (1.1) 436 (85) 208 (58) 92 (19)
Sex
Men 201 5.6 (1.1) 419 (81) 195 (51) 90 (18)
Women 272 5.0 (1.1) 448 (86) 218 (61) 93 (19)
Oral contraceptive
No 99 5.2 (1.0) 418 (69) 198 (44) 87 (15)
Yes 54 4.0 (0.9) 511 (92) 274 (69) 101 (21)
Age (year)
£ 45 223 5.2 (1.2) 429 (89) 206 (63) 89 (18)
> 45 250 5.3 (1.0) 442 (82) 210 (53) 94 (19)
Smoke
No 305 5.3 (1.1) 435 (86) 209 (57) 91 (19)
Yes 168 5.3 (1.2) 436 (85) 207 (59) 92 (19)
Alcohol (drinks per day)
None 111 5.1 (1.1) 442 (80) 210 (52) 93 (18)
£ 1 222 5.2 (1.2) 435 (86) 210 (63) 91 (19)
2–4 124 5.4 (1.1) 429 (88) 203 (54) 91 (19)
5–10 11 5.7 (1.3) 440 (107) 201 (57) 96 (23)
BMI (kg m)2)
£ 26 275 5.4 (1.2) 418 (80) 198 (55) 88 (17)
> 26 193 5.0 (1.0) 461 (85) 223 (58) 97 (20)
N, Population; F, factor; BMI, body mass index.
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developing thrombosis. We evaluated the clinical inventory
(seven procoagulants and two anticoagulants) of the non-
diseased control group from the LETS population and
developed individual TF-initiated (5 pM) thrombin generation
curves utilizing our numerical simulation model Clot Speed II.
The use of the numerical simulation model allowed us to
combine the results of the individual pro- and anticoagulant
compostion into an ensemble, which described the hypothet-
ical progress of thrombin formation. Each individual’s
hemostatic curve was translated into a deﬁned pattern and
used as an evaluation tool for the subsets of the non-diseased
population.
When all of the individualized dynamic thrombin genera-
tion curves are grouped, the standard deviation of the curve
is approximately 50% of the mean. When we deﬁned
subpopulations based upon the time to reach maximum
levels of thrombin generated, groups could be identiﬁed that
deviated by  2 orders of magnitude from the mean. At one
extreme, individuals reached maximum levels 3 min quicker
than the mean and also had higher maximum levels,
whereas at the other extreme, individuals took almost 4 min
longer to reach maximum levels and had lower levels of
thrombin generated. We speculate that these hypothetical
constructs imply categories of risk. Each individual displays
a unique thrombin generation curve. The wide variation
between analyses implys that thrombin generation is indi-
vidualized and suggests that coagulant hemostatic responses
and hence sensitivity for thrombosis will be different for
each individual.
When we evaluated the initiation, propagation and termin-
ation phases for each individual based upon thrombin param-
eters, we saw a wide spread of values. The time to 10 nM
thrombin varied over 3-fold (2.9–9.5 min), maximum levels of
thrombin varied over  4-fold (200–780 nM), maximum rates
varied  4.8-fold and total thrombin varied  4.5-fold within
the control population. Because of the wide span in these
parameters any one of them can potentially be useful in
evaluating individuals for hemostatic disorders. It is interesting
that the time to 10 nM thrombin and the maximum level of
thrombin within this large population overlapped with our
smaller empiric whole-blood studies [26], with the same TF
stimulus.
From the work by many investigators, we know that
thrombin generation is crucial to the hemostatic process
[31,43,61]. Many studies have also identiﬁed thrombotic risk
factors such as sex, obesity, and oral contraceptive use. This
study shows that dynamic thrombin generation in the
normal population is inﬂuenced by these same risk factors.
Of the determinants studied, the greatest inﬂuence on
thrombin generation was in the use of oral contraceptives.
All of the thrombin parameters increased towards a
potentially prothrombotic pattern in women using oral
contraceptives. These potentially prothrombotic patterns
were also seen in some of the other categories: women
over men, both men and women who were >45 years old
and individuals with a BMI >26 kg m)2. By comparing
these patterns of thrombin generation we may be able to
predict who is at risk of disease.
We conclude from these studies that no single factor con-
tributes overwhelmingly to the overall proﬁle in the normal
population. It is the synergy between the procoagulants,
anticoagulants and the inﬂuence from other risk factors. When
simulations for each individual were performed by holding
each protein constant, the inﬂuence on the simulation varied by
<9%. The largest change occurred to the maximum level of
thrombin generated when associated with FVIII. Total
thrombin was affected only when associatedwith prothrombin;
which correlates with previous in vitro observations that
prothrombin as an individual analyte had the greatest inﬂuence
on thrombin generation [62]. Thus, thrombin parameters
either individually or potentially in combination can be utilized
to develop a composite proﬁle for an individual.
These studies generate hypothetical thrombin generation
proﬁles which do not include the contribution of the antico-
agulant protein C pathway, the contribution of platelets (which
were not measured in the LETS population), the contact
pathway or the vasculature. The numerical model that was
used for these studies includes all the plasma pro- and anti-
components of the TF pathway to thrombin generation that
are evaluated in current laboratories; and shows high correla-
tion to our in vitro whole-blood systems and synthetic plasmas
[26,49–52]. These numerical simulations allow for the full
proﬁle of thrombin generation, which surpasses the current
assays that manage the hemostatic balance without assessing
the bulk of coagulation.
Continued studies to evaluate non-diseased individuals with
a combinatorial approach to thrombin generation for poten-
tially prothrombotic or protection from thrombosis patterns
may be informative to predict who is at thrombotic risk. In
addition, clinical evaluation and the inﬂuence of classical risk
factors must be considered from an integrated individualized
view.
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